Cytokine storm in COVID-19: immunopathogenesis and therapy

C Zanza, T Romenskaya, AC Manetti, F Franceschi… - Medicina, 2022 - mdpi.com
A cytokine storm is a hyperinflammatory state secondary to the excessive production of
cytokines by a deregulated immune system. It manifests clinically as an influenza-like …

COVID-19 therapeutics: Challenges and directions for the future

PC Robinson, DFL Liew, HL Tanner… - Proceedings of the …, 2022 - National Acad Sciences
The emergence of SARS-CoV-2 triggering the COVID-19 pandemic ranks as arguably the
greatest medical emergency of the last century. COVID-19 has highlighted health disparities …

[PDF][PDF] Therapeutics and COVID-19: living guideline, 16 September 2022

World Health Organization - 2022 - apps.who.int
As of August 2022, there have been over 572 million confirmed cases of COVID-19 (9). The
pandemic has thus far claimed approximately 6.39 million lives (9). Vaccination is having a …

[HTML][HTML] ESCMID COVID-19 living guidelines: drug treatment and clinical management

M Bartoletti, O Azap, A Barac, L Bussini… - Clinical Microbiology …, 2022 - Elsevier
Abstract Scope In January 2021, the ESCMID Executive Committee decided to launch a new
initiative to develop ESCMID guidelines on several COVID-19-related issues, including …

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

RECOVERY Collaborative Group, PW Horby… - Medrxiv, 2021 - medrxiv.org
Background REGEN-COV is a combination of 2 monoclonal antibodies (casirivimab and
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV …

Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European …

S Cesaro, P Ljungman, M Mikulska, HH Hirsch… - Leukemia, 2022 - nature.com
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel virus that spread
worldwide from 2019 causing the Coronavirus disease 19 (COVID-19) pandemic. SARS …

[HTML][HTML] Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

RECOVERY Collaborative Group - The Lancet Respiratory Medicine, 2021 - Elsevier
Background Colchicine has been proposed as a treatment for COVID-19 based on its anti-
inflammatory actions. We aimed to evaluate the efficacy and safety of colchicine in patients …

ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up

Cardiovascular Research, 2022 - academic.oup.com
Aims Since its emergence in early 2020, the novel severe acute respiratory syndrome
coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels …

Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications

N Potere, MG Del Buono, R Caricchio, PC Cremer… - …, 2022 - thelancet.com
A hyperinflammatory response during severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection crucially worsens clinical evolution of coronavirus disease 2019 …

Potent inhibitory activities of the adenosine analogue cordycepin on SARS-CoV-2 replication

AM Rabie - Acs Omega, 2022 - ACS Publications
Nucleoside analogues are among the most successful bioactive classes of druglike
compounds in pharmaceutical chemistry as they are well-known for their numerous effective …